% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ose:167838,
      author       = {J. Ose and B. Gigic and S. Brezina and T. Lin and A. Baierl
                      and A. J. M. R. Geijsen and E. van Roekel and N. Robinot and
                      A. Gicquiau and D. Achaintre and P. Keski-Rahkonen and F. J.
                      B. v. Duijnhoven and T. Gumpenberger and A. N. Holowatyj and
                      D. E. Kok and A. Koole and P. Schrotz-King$^*$ and A. B.
                      Ulrich and M. Schneider and A. Ulvik and P.-M. Ueland and M.
                      P. Weijenberg and N. Habermann and A. Scalbert and A. Gsur
                      and C. M Ulrich},
      title        = {{T}argeted {P}lasma {M}etabolic {P}rofiles and {R}isk of
                      {R}ecurrence in {S}tage {II} and {III} {C}olorectal {C}ancer
                      {P}atients: {R}esults from an {I}nternational {C}ohort
                      {C}onsortium.},
      journal      = {Metabolites},
      volume       = {11},
      number       = {3},
      issn         = {2218-1989},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2021-00582},
      pages        = {129},
      year         = {2021},
      abstract     = {The identification of patients at high-risk for colorectal
                      cancer (CRC) recurrence remains an unmet clinical need. The
                      aim of this study was to investigate associations of
                      metabolites with risk of recurrence in stage II/III CRC
                      patients. A targeted metabolomics assay (128 metabolites
                      measured) was performed on pre-surgery collected EDTA plasma
                      samples from n = 440 newly diagnosed stage II/III CRC
                      patients. Patients have been recruited from four prospective
                      cohort studies as part of an international consortium:
                      Metabolomic profiles throughout the continuum of CRC
                      (MetaboCCC). Cox proportional hazard models were computed to
                      investigate associations of metabolites with recurrence,
                      adjusted for age, sex, tumor stage, tumor site, body mass
                      index, and cohort; false discovery rate (FDR) was used to
                      account for multiple testing. Sixty-nine patients $(15\%)$
                      had a recurrence after a median follow-up time of 20 months.
                      We identified 13 metabolites that were nominally associated
                      with a reduced risk of recurrence. None of the associations
                      were statistically significant after controlling for
                      multiple testing. Pathway topology analyses did not reveal
                      statistically significant associations between recurrence
                      and alterations in metabolic pathways (e.g., sphingolipid
                      metabolism p = 0.04; pFDR = 1.00). To conclude, we did not
                      observe statistically significant associations between
                      metabolites and CRC recurrence using a well-established
                      metabolomics assay. The observed results require follow-up
                      in larger studies.},
      keywords     = {colorectal cancer (Other) / recurrence (Other) / targeted
                      metabolomics (Other)},
      cin          = {C120},
      ddc          = {540},
      cid          = {I:(DE-He78)C120-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33668370},
      doi          = {10.3390/metabo11030129},
      url          = {https://inrepo02.dkfz.de/record/167838},
}